Serum adenosine deaminase activity and coronary artery disease: a retrospective case-control study based on 9929 participants.
adenosine
adenosine deaminase
coronary artery disease
Journal
Therapeutic advances in chronic disease
ISSN: 2040-6223
Titre abrégé: Ther Adv Chronic Dis
Pays: United States
ID NLM: 101532140
Informations de publication
Date de publication:
2019
2019
Historique:
received:
07
08
2019
accepted:
30
10
2019
entrez:
17
12
2019
pubmed:
17
12
2019
medline:
17
12
2019
Statut:
epublish
Résumé
Adenosine deaminase (ADA) regulates purine metabolism through the conversion of adenosine to uric acid (UA). Adenosine and UA are closely associated with cardiovascular events, but the correlation between serum ADA activity and coronary artery disease (CAD) has not been defined. We performed a hospital-based retrospective case-control study that included a total of 5212 patients with CAD and 4717 sex- and age-matched controls. The serum activity of ADA was determined by peroxidase assays in an automatic biochemistry analyzer. Serum ADA activity in the CAD group (10.08 ± 3.57 U/l) was significantly lower than that of the control group (11.71 ± 4.20 U/l, Serum ADA activity is significantly attenuated in patients with CAD, particularly in MI. We propose a mechanism by which the body maintains adenosine levels to protect the cardiovascular system in the event of CAD.
Sections du résumé
BACKGROUND
BACKGROUND
Adenosine deaminase (ADA) regulates purine metabolism through the conversion of adenosine to uric acid (UA). Adenosine and UA are closely associated with cardiovascular events, but the correlation between serum ADA activity and coronary artery disease (CAD) has not been defined.
METHODS
METHODS
We performed a hospital-based retrospective case-control study that included a total of 5212 patients with CAD and 4717 sex- and age-matched controls. The serum activity of ADA was determined by peroxidase assays in an automatic biochemistry analyzer.
RESULTS
RESULTS
Serum ADA activity in the CAD group (10.08 ± 3.57 U/l) was significantly lower than that of the control group (11.71 ± 4.20 U/l,
CONCLUSIONS
CONCLUSIONS
Serum ADA activity is significantly attenuated in patients with CAD, particularly in MI. We propose a mechanism by which the body maintains adenosine levels to protect the cardiovascular system in the event of CAD.
Identifiants
pubmed: 31839921
doi: 10.1177/2040622319891539
pii: 10.1177_2040622319891539
pmc: PMC6900608
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2040622319891539Informations de copyright
© The Author(s), 2019.
Déclaration de conflit d'intérêts
Conflict of interest statement: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Pharmacol Ther. 2007 Dec;116(3):428-36
pubmed: 17915331
Circ Res. 1983 Jul;53(1):42-51
pubmed: 6861296
BMC Endocr Disord. 2018 Aug 20;18(1):58
pubmed: 30126383
Clin Chim Acta. 2017 Jan;464:195-199
pubmed: 27884754
Cardiology. 2007;108(4):275-81
pubmed: 17287605
Dis Markers. 2018 Oct 23;2018:1236837
pubmed: 30425752
Med Res Rev. 2001 Mar;21(2):105-28
pubmed: 11223861
Pharmacol Ther. 2013 Dec;140(3):239-57
pubmed: 23859953
Arch Bronconeumol. 2019 Jan;55(1):23-30
pubmed: 30612601
J Biol Chem. 1979 Feb 25;254(4):1217-26
pubmed: 762125
Can J Physiol Pharmacol. 2016 Mar;94(3):272-7
pubmed: 26762617
Arch Med Res. 2011 Nov;42(8):677-85
pubmed: 22154679
Diabetes Metab J. 2011 Apr;35(2):149-58
pubmed: 21738897
J Thorac Cardiovasc Surg. 2012 Sep;144(3):697-703
pubmed: 22336756
Circ Res. 1993 Mar;72(3):571-8
pubmed: 8381722
Clin Exp Rheumatol. 2003 Jan-Feb;21(1):87-90
pubmed: 12673895
EXCLI J. 2014 Feb 03;13:58-66
pubmed: 26417242
Circulation. 2002 Jan 29;105(4):E9070
pubmed: 11831213
Blood. 1985 Jun;65(6):1318-24
pubmed: 3922455
Dis Markers. 2003-2004;19(1):27-31
pubmed: 14757944
Eur J Prev Cardiol. 2016 Mar;23(5):502-10
pubmed: 25956428
Nitric Oxide. 2018 Dec 1;81:21-27
pubmed: 30300735
Am J Cardiol. 1997 Jun 19;79(12A):2-10
pubmed: 9223356
Orphanet J Rare Dis. 2018 Apr 24;13(1):65
pubmed: 29690908
Sci Rep. 2015 Jun 05;5:10987
pubmed: 26046576
Am J Physiol. 1986 Apr;250(4 Pt 2):H579-83
pubmed: 3963215
Heart. 2013 Jun;99(11):759-66
pubmed: 23343689
Clin Chem Lab Med. 2002 May;40(5):493-5
pubmed: 12113294
JACC Cardiovasc Interv. 2014 Jun;7(6):581-91
pubmed: 24835328
Med Hypotheses. 2006;67(2):371-4
pubmed: 16600525
Clin Exp Rheumatol. 1998 Sep-Oct;16(5):583-6
pubmed: 9779308
J Nutr Biochem. 2004 Feb;15(2):64-79
pubmed: 14972346
J Am Coll Cardiol. 2001 Dec;38(7):1850-8
pubmed: 11738284
Anal Chem. 2012 Apr 17;84(8):3593-8
pubmed: 22416759
Am J Physiol Heart Circ Physiol. 2008 May;294(5):H2158-65
pubmed: 18310516
J Microbiol Immunol Infect. 2007 Aug;40(4):288-92
pubmed: 17712462